Roquefort Therapeutics (LON:COIL) Trading Down 5% – What’s Next?

Roquefort Therapeutics plc (LON:COIL)’s stock price was down 5% during mid-day trading on Wednesday . The stock traded as low as GBX 9.50 and last traded at GBX 9.50. Approximately 310,553 shares changed hands during mid-day trading, an increase of 18% from the average session volume of 262,156 shares. The stock had previously closed at GBX 10.

Roquefort Therapeutics Price Performance

The stock has a fifty day moving average of GBX 10.29 and a 200 day moving average of GBX 10.28. The stock has a market cap of £41.23 million, a price-to-earnings ratio of -0.44 and a beta of 0.05. The company has a debt-to-equity ratio of 8.18, a current ratio of 0.63 and a quick ratio of 3.07.

Roquefort Therapeutics (LON:COIL) last issued its quarterly earnings results on Wednesday, May 6th. The company reported GBX (2.19) earnings per share for the quarter. Roquefort Therapeutics had a negative return on equity of 18.71% and a negative net margin of 57,057.07%.

Roquefort Therapeutics Company Profile

Coiled Therapeutics (AIM: COIL) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments. The Company is also assessing its STAT-6 siRNA programme for immunology indications.